Home > For Investors > Portfolio Companies > Thermalin Diabetes, LLC

Portfolio Companies

Thermalin Diabetes, LLC

LinkedIn Twitter

Thermalin Diabetes is developing clinically-superior, second generation insulin analogs for the rapidly growing $12 billion insulin market.

Thermalin's patent pending compounds include rapid-, intermediate- and long-acting analogs. With patents expiring on existing analogs in the next three to four years, Thermalin looks to form partnerships with large pharmaceutical companies that wish to market superior, next generation insulin therapies.

Initial JumpStart Investment: March 2010

For more information on Thermalin Diabetes, contact: Lynn-Ann Gries

Thermalin Diabetes Inc.
$1M grant will help researchers develop “smart insulin” as a safer option for type 1 diabetes
Thursday, March 14, 2013 Thanks to a new three-year, $1 million grant, a group of researchers at Case Western Reserve University are continuing to develop and test a form of glucose-responsive insulin that may someday be able to reduce the risk of dangerous hypoglycemic episodes in people with type 1 diabetes. Read More
Big Market, Bigger Mission
Tuesday, January 25, 2011

In an interview with JumpStart, Richard Berenson, CEO of Thermalin Diabetes, talked about how his company's success could change the lives of millions and put him in a position to help other entrepreneurs. Read Richard's story.

Read More